CN
Genecradle Therapeutics CO.,LTD.
About Us
GeneCradle Story
Carrying lanterns and moving forward, weaving the cradle of gene medicine
The origin of GeneCradle
GeneCradle, Cradle of advanced gene therapies
Gene is the root word of gene, and Cradle means "basket". GeneCradle means the basket for discovering advanced gene therapy drugs, and it is also the cradle of hope for patients with rare diseases. The Chinese name of GeneCradle means that we have gathered "brocade" into a "basket", which means to make good medicines for patients with rare diseases in China and even the world, and to make gene medicines that patients can afford.
In the brand logo of GeneCradle, the overall font is bravely moving forward with a broken bamboo momentum, expressing the GeneCradle people's unyielding sense of mission in the field of gene drug research and development. Our mission is to promote China's rare disease gene drugs from basic to clinical and market, to benefit patients and their families.
Company Milestones
The GeneCradle team is composed of virology research experts from the National Key Laboratory of the Chinese Center for Disease Control and Prevention, and is one of the earliest scientific researchers in China engaged in the research and development of key technologies for gene therapy and viral vectors.
1990
Founder Dr. Wu Xiaobing conducts AAV-related research at the National Key Laboratory of the Chinese Center for Disease Control and Prevention.
2003
The founding team successfully applied for the first clinical trial of AAV gene drug for the treatment of hemophilia B in China.
2014
Early team members began to conduct research on gene therapy for rare diseases, disease mechanisms and drug design in the form of a non-profit scientific research unit.
2018
GeneCradle was formally established with the goal of bringing the gene drugs developed into the clinic, hoping to truly solve clinical problems and become a permanent drug treatment solution.
2019
GeneCradle's first batch of gene drugs GC101 and GC301 completed concept verification, which coincided with the launch of the first SMA gene drug zolgensma in Europe and the United States. The high market price made us feel the weight of responsibility on our shoulders even more. For drug development, we raced against time.
2020
This year we have gained more like-minded partners and received more attention and support, which enabled us to invest more funds in preclinical projects and research and development.
2021
Our team stood at the starting line of clinical trials, participating in this long-distance race as a contestant for the first time. To this end, we strengthened the company's quality management, determined the quality policy of "originating from needs and benefiting patients", and built an ISO9001 quality management system around it.
2022
As the starting gun sounded, we chose to conduct registration clinical trials for different types of spinal muscular atrophy and Pompe disease separately to expand the population that can use the drug as much as possible.
2023
In order to reach the next check-in point in the long-distance race, we set the goal of "no stalling, no empty step".
2024
We are hearing more and more from patients and families, and the communication is becoming closer.
Quality Policy

  • Derived from demand

  • Courage to innovate

  • Dedicated to design

  • Strict verification

  • Proficient in manufacturing

  • Keep improve

  • Benefits to patients

Derived from demand:GeneCradle's product development projects are all based on unmet clinical needs

Courage to innovate:Gene therapy drug development is a disruptive technology field that lacks mature technology and product standards. It is necessary to "carry on the torch and move forward" to establish standards. Therefore, the team needs to have the courage to innovate and maintain the ability to innovate continuously.

Specialize in design:The design of gene therapy drugs requires an extremely high level of specialization, a deep understanding of the disease, and a team with professional gene therapy theory, technical knowledge, and practical experience. The company must remain advanced in its drug design technology.

Strict verification:Gene therapy drugs require multi-dimensional and multi-stage verification, including principle verification, concept verification, non-clinical research, clinical trials and other processes, requiring rigorous compliance and meeting requirements in each verification process.

Expertise in manufacturing:The company strives for excellence in product production processes and product quality, including advanced production equipment and facilities, quality inspection systems, and GMP standards throughout the entire production process, and continuously improves process technology and quality standards.

Keep improving:Implement the concept of continuous improvement in the operation of the company system and continuously improve the company's quality management.

Benefits to patients:Keep in mind that drugs are used to cure diseases and save lives, and the purpose of drug development is to benefit patients. We must always uphold the patient-centered concept and focus on the long-term benefits of drugs on patients' lives and quality of life.

Company Culture
Honor
Postdoctoral Research Station
Postdoctoral Research Station
High-tech Enterprise Certificate
High-tech Enterprise Certificate
National Intellectual Property Advantage Enterprise
National Intellectual Property Advantage Enterprise
Beijing's
Beijing's "Specialized, Refined, Specialized and Innovative" Small and Medium Enterprises
Intellectual Property Management System Certification
Intellectual Property Management System Certification
Quality Management System Certification
Quality Management System Certification